화농성 한선염(HS) : 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(2025-2035년)

Hidradenitis Suppurativa (HS) Market Outlook

Thelansis's "Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hidradenitis Suppurativa treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hidradenitis Suppurativa (HS) Overview

Hidradenitis suppurativa is a chronic, systemic inflammatory follicular disorder characterized by recurrent, painful deep-seated nodules, abscesses, draining sinus tracts, and progressive scarring. Although lesions manifest anatomically in intertriginous zones rich in apocrine glands, the primary pathobiology is rooted in hyperkeratosis and occlusion of the terminal hair follicle infundibulum followed by follicular rupture, immune dysregulation, and secondary microbial propagation. Diagnosis is clinical, utilizing the Hurley staging system to direct intervention and tracking metabolic comorbidities. Management in 2026 transitions rapidly from acute lifestyle and empiric antibiotic suppression to target-specific biological therapies for moderate-to-severe disease. While TNF-alpha inhibition remains foundational, molecular strategies widely utilize advanced interleukin-17A and interleukin-17A/F inhibitors to achieve sustained skin clearance and reduce inflammatory tunnel formation, complemented by wide surgical excision or deroofing procedures for anatomically fixed fibrotic disease structures.

Key Highlights

• In France, diagnosed Hidradenitis Suppurativa (HS) cases are projected to increase from 138,486 in 2025 to 178,286 by 2035.
• HS is a chronic, recurrent inflammatory skin disease associated with painful lesions, abscess formation, and progressive scarring.
• The disease imposes a substantial physical and psychosocial burden, significantly affecting patients' quality of life.
• Delayed diagnosis and limited long-term treatment options continue to contribute to persistent disease activity and unmet patient needs.

Market Overview

• The France HS market is projected to grow from $205M in 2025 to $620M by 2035.
• Market growth is driven by:
• Increasing adoption of biologic therapies targeting key inflammatory pathways
• Growing disease awareness and improved diagnosis of moderate-to-severe HS cases
• Future growth will depend on the successful development of novel targeted therapies capable of achieving sustained disease control and improving long-term patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Avalo Therapeutics, Inc.
• ACELYRIN Inc.
• Incyte Corporation
• Novartis Pharmaceuticals
• UCB Biopharma SRL
• Aclaris Therapeutics, Inc.
• Takeda
• Sanofi
• Merck Sharp & Dohme LLC
• Sonoma Biotherapeutics, Inc.
• Almirall, S.A.
• Shanghai Huaota Biopharmaceutical Co., Ltd.
• Eli Lilly and Company
• AbbVie
• Insmed Incorporated
• Pfizer
• Boehringer Ingelheim
• MoonLake Immunotherapeutics AG
• Vanda Pharmaceuticals
• Janssen Research & Development, LLC
• Bluefin Biomedicine, Inc.
• Navigator Medicines, Inc.
• Sinocelltech Ltd.
• Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
• Zura Bio Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)